{
    "clinical_study": {
        "@rank": "134594", 
        "acronym": "RAP", 
        "arm_group": [
            {
                "arm_group_label": "Sirolimus", 
                "arm_group_type": "Experimental", 
                "description": "Fixed oral dose of 3 mg Sirolimus (blinded) once weekly for 24 months."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Fixed oral dose of placebo (blinded) once weekly for 24 months."
            }
        ], 
        "brief_summary": {
            "textblock": "Sirolimus (SIR) has lead to a reduction of overall kidney size, a decrease in cyst density\n      and general tubular cell proliferation in animal models, and to a reduction of the increase\n      in creatinine and blood urea nitrogen by 34 and 39 percent respectively, as well as a\n      reduction of cyst proliferation, expressed by a 30 percent reduction of overall kidney\n      enlargement, a reduction in general cyst volume, and a reduction of the cyst volume density\n      in the renal cortex in humans.\n\n      However, despite promising data from animal- and in vivo studies, most mammalian target of\n      rapamycin  inhibitor (mTOR-I) studies in patients with autosomal-dominant polycystic kidney\n      disease (ADPKD) produced only subtle if any clinically relevant effects on cyst growth and\n      the preservation of renal function.\n\n      In this study we will investigate if pulsed administration of SIR in a fixed weekly oral\n      dose of 3 mg over 24 months compared to placebo significantly reduces cyst growth and\n      preserves excretory renal function in patients with ADPKD and an estimated glomerular\n      filtration (eGFR) rate below 60 mL/min per 1.73m2."
        }, 
        "brief_title": "Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Polycystic Kidney, Type 1 Autosomal Dominant Disease", 
            "Polycystic Kidney, Type 2 Autosomal Dominant Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Polycystic Kidney Diseases", 
                "Polycystic Kidney, Autosomal Dominant"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ADPKD, as confirmed by history, ultrasound, computed- or magnetic resonance\n             tomography\n\n          -  Eighteen years of age, or older\n\n          -  Baseline eGFR below 60 mL/min per 1.73m2\n\n          -  Negative serum pregnancy test prior to administration of sirolimus and agreement to\n             use contraception throughout the study and three months after\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Need for renal replacement therapy\n\n          -  Pregnancy/lactation\n\n          -  Plans to become pregnant in the near future\n\n          -  Refusal to use sufficient contraception\n\n          -  Proteinuria as defined as protein:creatinine ratio >1000 or >1g/d, respectively\n\n          -  History of life threatening complications of ADPKD\n\n          -  Evidence of active systemic- or localized major infection\n\n          -  Evidence of infiltrate or consolidation on chest X-ray\n\n          -  Use of any investigational drug or -treatment up to 4 weeks prior to enrolment and\n             during the study\n\n          -  Known allergy/hypersensitivity to sirolimus and its derivatives\n\n          -  Medication that will interfere with the cytochrome P450 (CYP3A4/CYP3A5) system\n\n          -  Total white blood cell count below or equal to 3000/mm3\n\n          -  Platelet count below or equal to 100.000/mm3\n\n          -  Fasting triglycerides above or equal to 400 mg/dL\n\n          -  Fasting total cholesterol above or equal to 300 mg/dL\n\n          -  Concomitant glomerular diseases\n\n          -  Psychiatric disorders and any condition that might prevent full comprehension of the\n             purposes and risks of the study\n\n          -  History of malignancy, with the exception of adequately treated basal cell- and\n             squamous cell carcinoma of the skin\n\n          -  HIV positivity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02055079", 
            "org_study_id": "V5.1/20.1.2013", 
            "secondary_id": [
                "2012-000550-60", 
                "15170", 
                "1060/2012"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Sirolimus", 
                "description": "Fixed oral dose of 3 mg sirolimus (blinded) once weekly for 24 months.", 
                "intervention_name": "Sirolimus", 
                "intervention_type": "Drug", 
                "other_name": "Rapamune"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Fixed oral dose of 3 mg placebo (blinded) once weekly for 24 months.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ADPKD", 
            "PKD", 
            "Polycystic kidney disease", 
            "Mammalian target of rapamycin", 
            "mTOR-I", 
            "Sirolimus"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "contact": {
                "email": "markus.riegersperger@meduniwien.ac.at", 
                "last_name": "Markus Riegersperger, MD", 
                "phone": "0043140400", 
                "phone_ext": "4391"
            }, 
            "contact_backup": {
                "email": "gere.sunder-plassmann@meduniwien.ac.at", 
                "last_name": "Gere Sunder-Plassmann, MD", 
                "phone": "0043140400", 
                "phone_ext": "4391"
            }, 
            "facility": {
                "address": {
                    "city": "Vienna", 
                    "country": "Austria", 
                    "zip": "1090"
                }, 
                "name": "Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna"
            }, 
            "investigator": [
                {
                    "last_name": "Markus Riegersperger, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Gere Sunder-Plassmann, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Austria"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease - The Vienna RAP Study", 
        "overall_contact": {
            "email": "markus.riegersperger@meduniwien.ac.at", 
            "last_name": "Markus Riegersperger, MD", 
            "phone": "0043140400", 
            "phone_ext": "4391"
        }, 
        "overall_contact_backup": {
            "email": "gere.sunder-plassmann@meduniwien.ac.at", 
            "last_name": "Gere Sunder-Plassmann, MD", 
            "phone": "0043140400", 
            "phone_ext": "4391"
        }, 
        "overall_official": [
            {
                "affiliation": "Medical University of Vienna", 
                "last_name": "Markus Riegersperger, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Medical University of Vienna", 
                "last_name": "Gere Sunder-Plassmann, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Fifty percent reduction in doubling of serum creatinine, or initiation of dialysis over a period of two years. Less or equal than 1.5 fold increase in serum creatinine without initiation of dialysis over two years is considered a beneficial outcome, increases in serum creatinine greater than 1.5 over two years or initiation of dialysis are considered a non-beneficial outcome.", 
            "measure": "Change in kidney function from baseline to month 24", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02055079"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical University of Vienna", 
            "investigator_full_name": "Markus Riegersperger, MD", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Safety, change in proteinuria, as indicated by albumin/creatinine- and protein/creatinine ratio, respectively.", 
            "measure": "Change of safety parameters from baseline to month 24", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline, 24 months"
        }, 
        "source": "Medical University of Vienna", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of Vienna", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}